- Conditions
- Heart Disease, Ischemic, Atherosclerosis, Coronary
- Interventions
- Gadolinium, Adenosine
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 63
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI, DCE-MRI, DSC-MRI, IV administration of gadolinium-containing contrast agent
- Device · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Primary Immunodeficiency
- Interventions
- Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- ISCHEMIC CARDIOMYOPATHY
- Interventions
- 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- li nguyen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Interventions
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Atrial Fibrillation, Coronary Artery Disease
- Interventions
- Regadenoson MRI, Gadobenate dimeglumine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Suspicion of, or Known Breast Cancer
- Interventions
- Radiology/MRI scan
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Magnetic Resonance Imaging Contrast Agents
- Interventions
- Magnevist, Dotarem, Gadovist
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 500 participants
- Timeline
- 1990 – 2019
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- ISCHEMIC CARDIOMYOPATHY
- Interventions
- Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diagnostic Self Evaluation, Central Nervous System Diseases
- Interventions
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
- Conditions
- Breast Cancer
- Interventions
- biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
- Procedure · Radiation · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 5
- States / cities
- San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
- Conditions
- Renal Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Meniere Disease
- Interventions
- Gadopentetate dimeglumine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Plaque Psoriasis.
- Interventions
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Sudden Cardiac Death
- Interventions
- Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
- Procedure · Other
- Lead sponsor
- Western Sydney Local Health District
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,058 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gadolinium Retention
- Interventions
- Surgery
- Procedure
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Myocardial Infarction
- Interventions
- Magnevist (Gadopentetate dimeglumine, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 6
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Tulsa, Oklahoma + 3 more
- Conditions
- Cancer
- Interventions
- Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
- Interventions
- Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
- Drug · Procedure
- Lead sponsor
- Donna Roberts
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Crohn Disease
- Interventions
- Bowel ultrasound, magnetic resonance enterography (MRE)
- Procedure
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
- Interventions
- Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas